Mineralys Therapeutics, Financials
| MLYS Stock | 13.11 0.59 4.71% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 24.95 | 23.7648 |
|
|
The financial analysis of Mineralys Therapeutics, is a critical element in measuring its lifeblood. Investors should not minimize Mineralys Therapeutics,'s ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Mineralys | Select Account or Indicator |
Understanding current and past Mineralys Therapeutics, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Mineralys Therapeutics,'s financial statements are interrelated, with each one affecting the others. For example, an increase in Mineralys Therapeutics,'s assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Mineralys Therapeutics,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mineralys Therapeutics, Common. Check Mineralys Therapeutics,'s Beneish M Score to see the likelihood of Mineralys Therapeutics,'s management manipulating its earnings.
Mineralys Therapeutics, Stock Summary
Mineralys Therapeutics, competes with Ultra Clean, Playtika Holding, Helmerich, Capital Clean, and Boyd Gaming. Mineralys Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US6031701013 |
| CUSIP | 603170101 |
| Location | Pennsylvania; U.S.A |
| Business Address | 150 N Radnor |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | mineralystx.com |
| Phone | 888 378 6240 |
Mineralys Therapeutics, Key Financial Ratios
| Return On Equity | -0.61 | ||||
| EBITDA | (84.66 M) | ||||
| Net Income | (71.9 M) | ||||
| Book Value Per Share | 4.76 X | ||||
| Market Capitalization | 623.1 M |
Mineralys Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mineralys Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Mineralys Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mineralys Therapeutics, competition to find correlations between indicators driving Mineralys Therapeutics,'s intrinsic value. More Info.Mineralys Therapeutics, Common is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, Mineralys Therapeutics,'s Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Mineralys Therapeutics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Mineralys Therapeutics, Systematic Risk
Mineralys Therapeutics,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mineralys Therapeutics, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Mineralys Therapeutics, correlated with the market. If Beta is less than 0 Mineralys Therapeutics, generally moves in the opposite direction as compared to the market. If Mineralys Therapeutics, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mineralys Therapeutics, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mineralys Therapeutics, is generally in the same direction as the market. If Beta > 1 Mineralys Therapeutics, moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Mineralys Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mineralys Therapeutics,'s growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Mineralys Therapeutics, growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Mineralys Therapeutics, November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Mineralys Therapeutics, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mineralys Therapeutics, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mineralys Therapeutics, Common based on widely used predictive technical indicators. In general, we focus on analyzing Mineralys Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mineralys Therapeutics,'s daily price indicators and compare them against related drivers.
| Downside Deviation | 3.58 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 20.98 | |||
| Value At Risk | (5.79) | |||
| Potential Upside | 6.27 |
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.